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ABSTRACT
Comparison of the Efficacy of Heparinized and 
Non-heparinized Normal Saline Solutions 
in Maintaining Patency of Arterial Catheters
By
Juanita K. Bogart
Although the need for heparin in flush solutions has not 
been established, the currently accepted standard of 
practice is to use heparinized solutions in arterial 
catheter flush devices. Exposure to heparin may place 
patients at risk for developing heparin-induced 
thrombocytopenia (HITP) and subsequent embolic events.
The purpose of the study was to test the null hypothesis 
that there is no significant difference in patency of 
arterial catheters maintained with heparinized or 
non-heparinized normal saline solutions. An experimental 
design using a convenience sample (N=31) and random 
assignment into experimental and control groups was used. 
There was no statistically significant difference in 
catheter patency between the two groups. The null 
hypothesis was supported.
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CHAPTER ONE 
INTRODUCTION
Invasive arterial cannulation for the purpose of 
monitoring arterial waveform and providing access for 
frequent blood sampling has become a routine part of 
modern intensive care. The patency of arterial catheters 
is generally maintained with a continuous flow of a 
solution containing heparin. A recent survey conducted by 
the American Association of Critical Care Nurses (AACN) 
reported that 96% of 1,072 randomly selected critical care 
nurses indicated that their institutions routinely 
heparinized arterial catheter flush solutions (AACN,
1990). Among the 96% who used heparinized solutions, 
varying amounts of heparin were used in the flush 
solution.
There are currently no standard guidelines for the 
maintenance of arterial catheters in critically ill 
patients. While heparinized flush solutions have been 
used to maintain the patency of arterial catheters since 
their inception (Johnson & Ito, 1969), concern about the 
risk of heparin-induced thrombocytopenia (HITP) has 
prompted discussion of heparin-free alternatives (Baldwin, 
1989; Warkentin & Kelton, 1989; Becker & Miller, 1989).
The reason for the efficacy of the flush solution is 
unclear. It may be caused by the anticoagulant or by the
continuous flow of fluid. Recent studies have evaluated 
the use of heparinized and non-heparinized solutions in 
peripheral access devices and have suggested that 
non-heparinized solutions may be as effective as 
heparinized solutions in maintaining arterial line patency 
(Epperson, 1984; Garrelts, LaRocca, Ast, Smith, & Sweet, 
1989; Ashton, Gibson, & Summers, 1990). There are to 
date, however, very few studies evaluating the 
contribution of heparin to line patency of arterial 
pressure monitoring systems, and the reported results are 
conflicting (Clifton, Branson, Kelly, Dotson, Record, 
Phillips, & Thompson, 1991; Hook, Reuling, Luettgen, 
Norris, Elsesser, & Leonard, 1987).
It is important that an effective and safe flush 
solution be identified. Nurses are in a key position to 
evaluate effectiveness of flush solutions since they are 
at the bedside and monitor the arterial waveform 24 hours 
a day.
Problem Statement
The currently accepted standard of practice is to use 
heparinized solutions in arterial catheter flush devices. 
The need for heparin in flush solutions has not been 
established. The use of heparinized solutions in 
peripheral access devices may not be necessary and may 
unduly place patients at risk for developing HITP and 
subsequent embolic events. Therefore, it is necessary to
determine if non-heparinized solutions would maintain 
patency of arterial catheters with as much efficacy as 
heparinized solutions.
Purpose
The purpose of this study was to determine if there 
was a significant difference in patency between arterial 
catheters maintained with heparinized normal saline flush 
solutions and those maintained with non-heparinized normal 
saline flush solutions. Patency was measured by 
acceptable square waveform test and free backflow of 
blood. Measurements were done every four hours for 
seventy-two hours after insertion of the catheter, or 
until the catheter and line were removed, whichever came 
first.
The research was one site of a multiple site study 
being conducted by the American Association of Critical 
Care Nurses called Thunder Project (Ledbetter, Ahrens, 
Brown, Gawlinski, Quinn, & Walsh, 1991). The data used 
for this study was collected from a 300 bed acute care 
hospital in the Midwest. The author was the AACN site 
coordinator for the hospital where data were collected 
(see Appendix A).
CHAPTER TWO 
LITERATURE AND CONCEPTUAL FRAMEWORK
Literature Review
Current and Past Nursing Practice. Arterial 
cannulation, the placement of an intra-arterial 
catheter, is indicated for continuous arterial pressure 
monitoring and to avoid the discomfort and injury from 
frequent arterial punctures. Arterial pressure is 
monitored by periodic assessment of the arterial waveform. 
The arterial waveform is a monitor tracing with visible 
fluctuations caused by stretching and increased tension 
within the arterial wall after each left ventricular 
ejection (Vitello-Cicciu, 1988). Patency of the arterial 
catheter is determined by a square wave test. This test 
is performed by activating a fast flush device on the 
arterial catheter solution tubing and assessing the 
resulting change in arterial waveform (Ledbetter et al.,
1991). Since 1959 heparinized flush solutions have been 
recommended to maintain arterial catheters (Johnson & Ito, 
1969; Gardner, Warner, Toronto, & Gaisford, 1970; Kaye, 
1983; Hudson-Civetta & Caruthers-Banner, 1983).
Johnson and Ito (1969) described a new pressurized 
tubing and flush system developed for monitoring arterial 
waveform and maintaining arterial catheter patency. They 
recommended the use of heparinized solution in a
continuous low volume flush system. They did not, 
however, specify the concentration of heparin needed or 
the preferred base solution.
Gardner et al. (1970) also described a similar 
continuous flow system for arterial catheter and line 
maintenance. They introduced the fast flush into the flow 
system. This produced the square-wave test, an indication 
of patency of the arterial catheter. They recommended the 
use of heparin in the flush solution, but did not indicate 
the optimal concentration.
Opinions vary regarding the amount of heparin to be 
added to the flush solution. Kaye (1983) indicated that 
2-4 units/ml. solution should be used. Hudson-Civetta and 
Caruthers-Banner (1983) recommended 10 units/ml.
A survey of randomly selected critical care nurses 
was conducted by AACN (AACN, 1990). Of the 1,072 who 
responded, 96% indicated that heparinized flush solutions 
were used for arterial lines in their institution. There 
was much variation in the concentration of heparin in the 
flush solutions used by the institutions. Thirty three 
and one-half percent of respondents (n = 349) indicated 
that their institutions used a 1:1 concentration of 
heparin in arterial lines, 51.4% (n = 551) used a 2:1 
concentration, only 9% (n = 97) used heparin 
concentrations stronger than 2:1, and 2% (n = 20) used 
non-heparinized solutions. Clinical nurse specialists
from one critical care unit indicated that they had not 
used heparinized solutions to maintain arterial catheter 
patency for over five years and had no complications that 
could be linked to the use of non-heparinized solution 
(Jiricka, M., & Schweiger, J., personal communication, 
December 14, 1990). This seems to support continuous flow 
rather than an anticoagulant for maintaining patency of 
arterial catheters.
Pregnancy and Use of Heparin. There are conflicting 
reports in the literature about the safety of using 
heparin during pregnancy. Andrew et al. (1985) injected 
radioactive heparin into sheep at 108-119 days gestation 
(term: 147 days). After 4 hours, blood samples were drawn 
from each mother and fetus for measurements of activated 
partial thromboplastin times and radioactivity. There was 
no detectable radioactivity or anticoagulant effect in any 
fetus. They concluded that heparin did not cross the 
placental barrier.
Ginsberg, Hirsh, Turner, Levine, and Burrows (1989) 
reviewed the literature and also reported that heparin was 
not found to cross the placental barrier. However, they 
reported that the use of heparin during pregnancy is 
problematic because of the potential adverse effects to 
the mother. These conflicting reports supported the 
decision to use pregnancy as an exclusion criteria for 
recruiting subjects in tbe present study since the fetus
could potentially be placed, at risk.
Heparin Induced Thrombocytopenia. According to Irvin 
(1990)/ heparin therapy is not without risk. The 
incidence of HITP may be much greater than reported.
HITP, a phenomenon in which heparin paradoxically causes 
platelet aggregation, may be the most serious adverse 
reaction associated with heparin use. The resulting 
thrombi are usually arterial. If an embolic event occurs, 
the results may be a stroke, myocardial infarction, 
pulmonary embolus, loss of a limb, or death.
Chang (1987), in a retrospective study, reviewed the 
charts of 23 clients who had received low-dose heparin 
therapy and were suspected to have developed HITP. Death 
occurred in 40% (n = 9) and 13% (n = 3) needed amputation 
of a limb. Thrombocytopenia occurred 6-13 days after 
initiation of the heparin therapy.
Becker and Miller (1989) described the incidence of 
HITP in clients who had experienced strokes. A literature 
review identified 600 cases of stroke victims. Over 50% 
of the reported cases were a result of HITP and a 
subsequent embolic event. Prospectively, they estimated 
that 10% of clients receiving heparin would develop HITP, 
and of those, 10% would have a thrombo-embolic event, 
resulting from even very small doses of heparin. There 
were no significant relationships between the amount of 
heparin received and the incidence of HITP. Severe cases
developed with doses as low as 240-500 units/day, an 
amount commonly received in arterial catheter flush 
solutions. In contrast to Chang (1987), who reported 
that thrombocytopenia occurred 6-13 days after heparin 
therapy was started, Becker and Miller (1989) reported 
that an immune mediated response with catastrophic results 
could occur within 30 minutes after a repeat exposure to 
heparin. Persistent sensitivity to heparin was found to 
last up to 28 months after initial exposure. The study 
was limited by the selection of only clients who had 
experienced strokes.
Warkentin and Kelton (1989) reviewed the literature 
and estimated the incidence of HITP to be 5% of those 
receiving heparin. They reported adverse reactions to 
include limb loss; myocardial infarction; pulmonary 
embolism; thrombotic strokes; thrombosis of the 
mesenteric, splenic, renal, and spinal arteries; adrenal 
thrombosis; and hemorrhage.
Flush Solutions. Most of the studies comparing the 
effects of heparinized and non-heparinized solutions on 
maintaining patency of catheters have been conducted in 
populations requiring intravenous peripheral access 
devices, more commonly called heparin locks. Epperson 
(1984) conducted a double-blind quasi-experiraental study 
with a convenience sample (N = 412). The hypothesis that 
flush solutions containing 0.9% sodium chloride injection
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alone were as effective as 0.9% sodium chloride injection 
containing either 10 or 100 units/ml. of heparin for 
preventing loss of patency in heparin-lock sites was 
supported. There were no statistically significant 
differences in length of patency of the device between the 
groups. A limitation of the study was the lack of random 
assignment into experimental and control groups. All 
subjects admitted to the study unit for two months 
received the first of the three flush solutions. After 
the initial two months a different solution was used for 
two months on all subjects admitted to the unit. The 
procedure was repeated for the third solution.
Garrelts et al. (1989) conducted a prospective 
randomized double-blind study on 147 subjects with a 
heparin lock. One group received heparin flushes, the 
other received normal saline flushes. Although there were 
no significant differences in phlebitis or loss of 
patency in the normal saline group, significantly more 
non-occlusive fibrin clots (p=<.001) were found at the tip 
of the catheter upon removal. There were no new onset 
stroke‘Or embolic events in any of the subjects. Some 
subjects from both groups refused to have the device 
changed every 72 hours as the study protocol required.
The data were adjusted to a set length of 72 hours_for 
these clients, even though the catheter was not removed 
until much later. The investigators in the study
speculated that the additional time beyond 72 hours may 
have allowed more time for fibrin clots to form before the 
catheter was inspected, thus affecting the results of the 
study.
A study by Ashton et al. (1990) used a convenience 
sample (N = 32) in a double-blind experimental design 
comparing the use of normal saline with 10 units of 
heparin/ml. and non-heparinized normal saline flush 
in heparin lock devices. The null hypothesis, that there 
was no difference in the effectiveness of non-heparinized 
and heparinized solutions in maintaining patency of 
heparin lock devices, was supported. The study was 
limited by the small sample size and non-random sampling.
There were only two studies found that compared the 
efficacy of heparinized and non-heparinized solutions in 
arterial catheters. Hook et al. (1987) used a convenience 
sample (N = 50) with non-random assignment into groups for 
a quasi-experimental study. The subjects selected were 
hospitalized for cardiovascular surgery. The solutions 
used in the study were plain lactated ringers in the 
experimental group and lactated ringers with 2.5 units 
heparin/ml in the control group. There was no . 
significant difference in patency variables, i.e. line 
irrigated easily, line drew easily, cuff pressure equaled 
monitor pressure +/- 10 mm Hg, and the line functioned 
properly. A good waveform was reported more frequently in
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the heparinized group than in the non-heparinized group 
(p=.03). There were three incidents of clot formation in 
the non-heparin group and none in the heparin group, 
however the difference in clot formation was not 
significant (p=.13). Most of the catheters had radial 
artery placement (n = 48) and were in place less than 72 
hours. The study was limited by the use of a convenience 
sample and non-random assignment into groups.
Clifton et al. (1991) used a double-blind 
experimental design with a small convenience sample 
(N = 30). The research question was: Does heparin prolong 
the functional lifespan of peripheral arterial catheters 
and is there a difference in systemic adverse effects?
The study design was for 40 subjects. Patency results 
were tested for significant differences after data 
collection was complete on 10, 20, and 30 subjects 
respectively. The study was stopped with 30 subjects 
because of significant differences found in arterial 
catheter patency (p=<.01). The arterial catheters flushed 
with 0.9% sodium chloride solution had a significantly 
greater loss of oatencv rate than catheters flushed with a 
4 units/ml heparin solution. The study was limited by 
all subjects having only,20 gauge radial catheters. The 
authors stated that they used only subjects with normal 
platelet counts and coagulation indices, yet they used a 
platelet count of less than 50,000/micrbTiter as inclusion
11
criteria. A level of less than 100,000/microliter is 
considered by many to be thrombocytopenic (Irvin, 1990; 
Chang, 1987; Warkenton & Kelton, 1989).
All arterial catheters place clients at risk 
for clot formation and subsequent thrombo-embolic events 
(Ledbetter et al., 1991). Although some studies reported 
fibrin clots in the catheters of subjects receiving 
non-heparinized flush solution, there were no reports of 
thrombo-embolic events (Hook et al., 1987; Garrelts et 
al., 1989). The literature does not support an increased 
risk associated with the use of non-heparinized flush 
solutions (Ashton et al., 1990; Hook et al., 1987; 
Epperson, 1984; Garrelts et al., 1989).
Conceptual Framework
Client/Client System. Neuman (1989) conceptualized 
the client/client system with concentric rings called 
flexible and normal lines of defense and lines of 
resistance which encircle a basic core (see Figure 1).
The client system includes five variables: physiological, 
referring to bodily structure and function; psychological, 
referring to mental processes and relationships; 
sociocultural, referring to combined social and cultural 
functions; developmental, referring to life developmental 
processes; and spiritual, referring to spiritual belief 
influence. In this study the client is defined as anyone 
who requires tbe placement of an arterial catheter for
12
Figure 1
Intact Vascular Flexible Line of Defense Normal Platelet
AggregationSystem with 
Adequate Peripheral 
and Central "
Circulation/^ ^ Normal Line of Defense Normal
Coagulation
Lines of Resistance '
Basic
Core
Vital \
Organ/Organ System 
and Extremities.
Neuman's Conceptual Model Applied to Heparinized Flush Solutions.
(Adapted _from.Neuman, B., . a n d . Y o u n g , 1972. ...A jnodel for teaching 
total person approach to patient problems. Nursing Research, 21, 265.)
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arterial waveform analysis or frequent blood sampling and 
is admitted to either one of the two Intensive Care Units 
(ICUs) of a hospital in the Midwest.
The basic core is composed of basic survival factors 
common to the species such as normal temperature range, 
genetic structure, response pattern, strength of organs 
and organ systems, and ego structure. These survival 
factors are necessary to maintain system integrity and 
life. For the purpose of this study the basic core is 
defined as any organ/organ system which sustains the life 
of the client. It also includes extremities which could 
require amputation secondary to a thromboembolic event.
The lines of resistance are a series of broken 
circles surrounding the basic core. They are activated 
following invasion by stressors of the normal line of 
defense. They contain certain factors which support the 
individual's basic core, thus protecting system integrity. 
Ineffectiveness of the lines of resistance in preventing 
or reversing the reaction to stressors leads to energy 
depletion and probable death. The line of resistance of 
interest to this study is an intact vascular system with 
adequate peripheral and central blood flow to extremities 
and organs/organ systems.
The normal line of defense is defined as the usual 
wellness state of the client. This is a state to which 
the client "has evolved. It is changed and adapted to over
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time. When the normal line of defense is penetrated by a 
stressor, symptomatology may begin to appear (Neuman,
1989, p. 29). Normal coagulation is considered to be the 
normal line of defense in this study. Normal coagulation 
includes a platelet count of greater than 
100,000/microliter with the rest of the coagulation 
process intact (Ledbetter et al., 1991).
The outermost ring, the flexible line of defense, is 
a buffer to protect the normal line of defense from insult 
by stressors. It is dynamic rather than stable and can be 
altered over a very short period of time, such as in 
emergent situations. Stressor impact, whether multiple or 
single, has the potential for reducing the effectiveness 
of the flexible line of defense. In this study the 
flexible line of defense is defined as normal platelet 
aggregation.
Environment. "The environment is broadly defined as 
all internal and external factors or influences 
surrounding the identified client or client system" 
(Neuman, 1989, p. 31). Stressors arise from the 
environment and can be internal (intrapersonal) in nature, 
external (interpersonal or extrapersonal) in nature, or a 
created environment (intra-, inter-, or extrapersonal) in 
nature. A stressor is anything which produces disharmony 
among the variables. More than one stressor may occur 
simultaneously. Stressors may vary in impact and reaction
15
produced. Heparin, arising from a created extrapersonal 
environment, is the stressor in this study.
Health. Wellness, or health, is defined as the 
condition in which all five variables are in harmony with 
the whole of the client. Health for the client is viewed 
"as being on a continuum and dichotomous with illness" 
(Neuman, 1989, p. 33). Disharmony among the variables 
reduces the wellness state and is considered illness.
HITP is an illness state that can result from insult by 
heparin to the normal line of defense, the coagulation 
process. In clients who are sensitive to it, heparin can 
alter the cell wall of platelets causing them to aggregate 
abnormally. This decreases the number of platelets for 
normal coagulation resulting in HITP. The aggregated 
platelets can lead to thrombus formation and subsequent 
embolic events (Irvin, 1990).
Nursing. Neuman's model has three levels of 
prevention. The first is primary prevention, such as 
reducing the possibility of encounter with stressors and 
strengthening the flexible line of defense. Secondary 
prevention consists of early case-finding and the 
treatment of symptoms. Tertiary prevention is the 
maintenance of stability, rehabilitation, and reeducation 
to prevent future occurrences.
The goal of nursing is to assist the individual to 
attain/maintain an optimal wellness level. Any means by
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which stressors can be reduced will decrease insults to 
the basic core and the potential for death. Eliminating 
exposure to the stressor heparin in arterial catheter 
flushes is a means of primary prevention. This is 
accomplished by reducing encounters with a stressor which 
has the potential for penetrating the flexible line of 
defense via alteration of platelet aggregation (Irvin,
1990) and disruption of the coagulation process, the 
normal line of defense, which results in HITP and the 
potential for a thromboembolic event. A thromboembolic 
event could lead to obstructions in the vasculature 
system, one line of resistance, causing loss of 
extremities or death of the client, which results from 
overwhelming insult to the basic core. Determining the 
efficacy of non-heparinized flush solution in arterial 
catheters will result in knowledge which when applied, 
will result in reducing insult to all lines of defense and 
resistance and to the basic core of clients.
Hypothesis
The following null hypothesis was tested: There 
will be no significant difference in patency of arterial 
catheters maintained with heparinized or non-heparinized 
normal saline solutions.
17
CHAPTER THREE 
METHODOLOGY
Design
The study, which was conducted at one site of a 
multi-site study by AACN, used an experimental design and 
compared subjects randomly assigned into two groups, those 
with heparinized arterial flush solution as the control 
group, and those with non-heparinized arterial flush 
solution as the experimental group. The heparinized flush 
solution was the standard solution used by the hospital 
and consisted of 2,000 units of heparin in one liter of 
0.9% sodium chloride (normal saline) solution. The 
non-heparinized solution was normal saline.
Written approval for human subjects use was obtained 
from human research review committee of Grand Valley State 
University (see Appendix B). Verbal approval to conduct 
the study was obtained from an institutional review panel 
in the hospital where data were collected.
Sample
A-convenience sample (N=31) was recruited from two 
ICUs of a hospital in the Midwest. Fifteen subjects were 
in the control (heparin) group and sixteen were in the 
experimental (no heparin) group. Age ranged from 34-84 
years with a mean of 68.94 years and a standard deviation 
of 10.81 years. Characteristics of the sample are listed
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in Table 1. Both units were similar in size and patient 
acuity and had a patient population that consisted of 
medical, surgical, and neuro-trauma patients.
Inclusion and exclusion criteria were consistent with 
those used by the AACN in Thunder Project (Ledbetter et 
al., 1991). Inclusion criteria consisted of the 
following:
- measurement of arterial pressure and/or drawing blood 
via arterial catheter required because of medical 
condition
- 18 years of age or older
- arterial catheter connected to monitoring equipment 
which could display waveform and fast flush
- enrolled in the study and placed in the appropriate 
randomly assigned group at the time the arterial 
catheter was inserted.
Exclusion criteria consisted of:
- known platelet count of less than 100,000/microliter 
at the time of insertion of the arterial catheter
- enrolled in the study at a previous time
- enrolled in an experimental drug protocol
- known sensitivity to heparin or a physician's 
order excluding heparin from the treatment plan
- pregnancy.
The use of drugs with anticoagulant effects were made note 
of on the data collection instrument, but were not cause
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Table 1
Characteristics of the Sample fN=311
n %
Gender
Male 16 51.61
Female 15 48.39
Ethnicity
Caucasian 28 90.32
Afro-American 3 9.68
Diagnosis
Medical 23 74.19
Surgical 8 25.81
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for exclusion from the study. This was consistent with 
the AACN study (Ledbetter et al., 1991).
Operational Definitions
Patency was defined as the maintenance of an 
unobstructed arterial catheter as measured by two 
criteria, acceptable square wave test and free backflow of 
blood from the catheter.
Acceptable square wave test was achieved when upon 
activation of the fast flush device, there was a rapid 
upstroke which terminated in a flat line at the maximal 
indicator on the tracing paper and, upon release of the 
fast flush device, there was a rapid and unimpeded 
downstroke approximating a 90 degree angle with a negative 
deflection below baseline and a return to the arterial 
waveform within 12/lOOths of a second (see Appendix C).
Free backflow of blood was defined as a flashback of 
blood in the tubing at the interface of the catheter and 
pressure tubing within one second when the stopcock was 
turned off to the transducer and opened to air.
Heparinized flush solution was 0.9% sodium chloride 
intravenous fluid containing the drug heparin in a 2:1 
concentration. The solution was infused continuously 
under 300 mm Hg. pressure.
Non-heparinized flush solution was 0.9% sodium 
chloride intravenous fluid without the addition of the
2 1
drug heparin. This solution was also infused continuously 
under 300 mm Hg. pressure.
Instrument
Data collection instruments (see Appendix D) were 
provided by AACN. The instruments included tracings of 
acceptable and dampened (non-acceptable) square waves to 
assist the raters in accurate identification. Also 
included on the instrument were checklists for arterial 
bag pressure, acceptable square wave, arterial backflow, 
and use of anticoagulants since the previous data 
collection time. Demographic and clinical data were 
collected on gender, age, ethnicity, primary diagnosis, 
pressure monitoring system used, type of unit subject was 
in at the time of the study, descriptives of the arterial 
catheter used, type of arterial flush solution used, and 
the use of any other arterial or central lines during the 
study.
Content validity for the instrument was established 
by a panel of experts from AACN with consideration of 
clinical practice and the literature (Ledbetter et al., 
1991). - The clinical indicators of arterial line patency 
that were used were suggested through research conducted 
by Clifton et al. (1991), Hook et al. (1987), and Kaye 
(1983).
Interratsr reliability for assessing patency and 
treatment of arterial lines in the two groups was
2 2
established and the protocol refined during Phase I and 
Phase II of a pilot study by AACN (Ledbetter et al.,
1991). During Phase I, preliminary instruments and 
protocols were tested at one site with 11 subjects. The 
data collection instrument was revised based on input from 
the site. The level of interrater reliability for the 
instruments, as established by AACN in the pilot studies, 
was not specified.
Two sites and 34 subjects were used for Phase II of 
the AACN pilot study. The purpose of this phase was to 
enlarge the number of subjects to identify data collection 
problems, continue evaluation of safety, and to test the 
revised instrument. During this phase it was identified 
that heparin and non-heparin lines were sometimes treated 
differently. The protocol was clarified and changes were 
made in the inservice material presented to the data 
collectors.
Phase III of the AACN pilot study consisted of 3 
additional sites and 21 subjects. The purpose of this 
phase was to validate the instrument and the inservice 
process and to continue monitoring the safety of the 
protocol. No changes were made in the instrument, 
inservice process, or protocol during this phase.
Procedure
Staff registered nurses were inserviced by the 
investigator. "The inservice consisted of viewing a video
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tape prepared by AACN that described the data collection 
protocol and data collection forms. The staff nurses were 
each given written guidelines for data collection (see 
Appendix E ). The procedure for obtaining informed consent 
was presented by the investigator. The staff nurses were 
given a square wave form self assessment (see Appendix F) 
to complete and return anonymously to the investigator. 
Fifty percent of the self assessments were completed and 
returned. Interrater reliability for waveform 
identification was established at .94, based on the self 
assessment. This may have been spuriously high because of 
the low return rate on the self assessments.
A master log with random assignment into groups was 
provided by AACN. As subjects were recruited into the 
study, the subject's hospital identification number was 
placed on the next available space on the master log. This 
made assignment into experimental or control group.
Subjects were recruited at the time consent for 
arterial catheter insertion was obtained. Informed 
consent to participate in the study (see Appendix G) was 
obtained from each subject, or the appropriate 
representative if the subject was too ill to give consent. 
Selection of the appropriate representative was determined 
by the standard practice of the hospital: a. spouse, b. 
adult child, c. parent, d. adult sibling, e. guardian.
Data were collected by unit staff registered
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nurses who had been inserviced on the data collection 
protocol. The time of the insertion of the catheter and 
demographic and clinical data were placed on the data 
collection instrument as soon as possible and less than 
four hours after the insertion. Four hour time intervals 
were calculated and the appropriate data collection 
points identified. Data collection was performed at the 
specified four hour intervals with an acceptable range of 
plus or minus one hour. Data collection continued for 
seventy-two hours or until the catheter was removed, 
whichever came first. The data collected at the four hour 
intervals were assessment of the arterial site, arterial 
waveform, fast flushform, and whether or not the pressure 
on the solution was at 300 mm Hg.
Risks were minimal. In rare circumstances 
thromboembolic events have occurred subsequent to the 
placement of any invasive catheter. There was no 
increased risk to the client because of the study (Ashton 
et al., 1990; Hook et al, 1987; Epperson, 1984; Garrelts 
et al., 1989).
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CHAPTER FOUR 
RESULTS
The results are reported according to demographic 
characteristics and patency assessment. Data were 
analyzed with the use of the chi-square statistic and 
student t-test to detect differences between groups and to 
determine statistical significance. The significance 
level was set at p<.05. The sample size was sufficient 
for two by two and two by three tables. A total of one
loss of patency in the no heparin group and no loss of
patency in the heparin group resulted in empty cells and
cells with an expected frequency of <5. Since the low
loss of patency violated an assumption of sample size for 
the chi-square statistic, a Yate's correction was used. 
Sample Characteristics
The groups were equivalent in demographic and 
arterial catheter characteristics. Fifteen subjects were 
in the control group and sixteen were in the experimental 
group. Arterial catheter characteristics are listed in 
Table 2 . Hours of data collection during catheter 
placement ranged from 20 to 72 hours with a mean time of 
59.74 hours (SD=I5.39). Some catheters were removed for 
reasons other than loss of patency before the 72 hour cut 
off for data collection. According to the AACN Thunder 
Project protocol, data collection stopped at 72 hours even
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Table 2
Arterial Catheter Characteristics (N=31^
Site --------------------
Radial 21 67.74
Femoral 8 25.81
Brachial 2 6.45
Length
<2 cm. 21 67.74
>4 cm. 10 32.26
Gauge
22 2 6.45
20 19 61.29
18 7 22.58
16 3 9.68
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though some catheters remained in place longer.
Characteristics of the sample according to group 
membership are shown in Table 3. Arterial catheter 
characteristics according to group membership are shown in 
Table 4. When the groups were compared for equivalence in 
age the student t-test was used. Mean age of the no 
heparin group was 71.60 years (SD=5.33). The mean age of 
the heparin group was 66.44 years (SD=13.91). The 
difference in mean age between the groups was not 
significant (T=1.38, df= 19.55, p=.18). All other 
variables were nominal level data for which the chi-square 
test was used. Although chi-square value varied among the 
variables, there were no significant differences between 
groups in gender, ethnicity, diagnosis, catheter site, 
catheter length, or catheter gauge.
Patencv Assessment
The hypothesis that there would be no significant 
difference in the patency of arterial catheters maintained 
with heparinized or non-heparinized normal saline 
solutions was supported. As shown in Table 5, only one 
subject lost patency of the arterial catheter. This 
subject was in the no heparin group. The registered nurse 
who determined that the catheter needed to be removed 
reported that there was bruising at the catheter site.
She removed the catheter and documented it as loss of 
patency. The charge nurse in the unit at the time
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Table 3
Sample Characteristics According to Group Membership
No Heparin Heparin
(n=16) (n=15)
Gender
Male 7 9 X^= .03
Female 8 7 df= 1
p= . 86
Ethnicity
Caucasian 14 14 X^= .00
Afro-American 1 2 df= 1
p=l.00
Diagnosis
Medical 12 11 X^= .09
Surgical 3 5 df= 1
p= .76
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Table 4
Arterial Catheter Characteristics 
According to Group Membership
Catheter Site 
Radial 
Femoral 
Brachial
No Heparin Heparin
(n=16) (n=15)
10
4
1
11
4
1
X2
X2= .02 
df= 2 
p= .99
Catheter Length
<2cm. 10
>4cm. 5
11
5
X2= .00 
df= 1
p=1.00
Catheter Gauge 
22 
20 
18 
16
1
9
3
2
1
10
4
1
X^= .49 
df= 3 
p— .92
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Table 5
Patencv Assessment
No,Heparin Heparin Total
(n= 16) (n= 15) (N=31)
Patency*
Maintained 14 16 30
Loss of 1 0 1
* x2=.001, df=l, p=.97
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reported that the bruising had been present prior to the 
placement of the catheter. A follow-up check of the 
medical record indicated that there were no untoward 
embolic events following the removal of the catheter.
The dependent variable in the hypothesis was patency. 
The independent variable was type of flush solution. Both 
variables were at the nominal level of measurement. The 
chi-square statistic with Yate's correction was used to 
determine if there was a statistically significant 
difference in catheter patency when heparinized and 
non-heparinized normal saline flush solutions were used. 
There was no significant difference in maintenance of 
patency between the groups (X =.001, df=l, p=.97).
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CHAPTER FIVE 
DISCUSSION
Exposure to the stressor heparin has been associated 
with life-threatening thromboembolic events (Irwin, 1990; 
Chang, 1987; Warkenton & Kelton, 1989; Becker & Miller, 
1989). Historically, heparin has been used to maintain 
arterial line patency despite the lack of empirical 
evidence supporting the need for it. Studies to provide 
empirical evidence to support the efficacy of 
hon-heparinized solutions in maintaining patency of 
arterial catheters have had conflicting results. Clifton 
et al. (1991) found that arterial catheters flushed with 
0.9% sodium chloride solution had a significantly greater 
loss of patency than catheters flushed with heparinized 
solution. Hook et al. (1987) found no significant 
differences in patency when arterial catheters were 
flushed with heparinized and non-heparinized solutions. 
Consistent with Hook et al. (1987), this study 
demonstrated no significant difference in arterial 
catheter patency between the catheters maintained with 
heparinized solutions and those maintained with 
non-heparinized solutions in equivalent groups.
The most frequent recipients of arterial catheters 
are clients who have multiple insults to all lines of 
resistance and to the basic core in many or all of the
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variables. Much of the nursing care provided to these 
clients is secondary or tertiary prevention as opposed to 
primary prevention. The Neuman Systems Model (Neuman, 
1989) provides a useful conceptual framework for studying 
primary prevention in these clients by eliminating the 
stressor of heparin in maintaining patency of arterial 
catheters. The placement of the arterial catheter is a 
created extrapersonal stressor which reduces the 
effectiveness of the lines of resistance by disrupting the 
vasculature system. Heparin in the flush solution is an 
additional stressor which may penetrate the flexible line 
of defense by altering platelet aggregation. Eliminating 
the additional external stressor, heparin, is a means of 
primary prevention.
This study built on the study of Hook et al. (1987). 
Both studies found no significant difference in the 
maintenance of patency of arterial catheters maintained 
with heparinized and non-heparinized solutions. This 
suggests that patency can be maintained in arterial 
catheters without stressing the client with heparin. The 
risk of HITP which results in insult to the basic core of 
the client should be considered before routinely using 
heparinized flush solutions to maintain catheter patency. 
Limitations
The study was limited by the small sample size 
(îi=3T). A larger sample size would reduce the possibility
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that a Type' II error was made. By using power analysis, 
AACN determined that a sample size of N=11,000 was needed 
(Ledbetter et al., 1991) for an alpha of .05 and power 
equal to .80.
All of the subjects in this study had medical or 
surgical diagnoses. Trauma, burns, and neurological 
insult are common diagnoses in critical care, but were not 
represented in the sample of this study. Because response 
to stressors may vary with diagnosis, it cannot be assumed 
that the results of this study would apply to any other 
than a medical or surgical population.
This study used only 0.9% sodium chloride as the 
flush solution for arterial catheters. The 0.9% sodium 
chloride solution was chosen because it was the customary 
solution for the hospital in which data were collected. 
According to the protocol for the AACN study (Ledbetter et 
al., 1991) other solutions such as dextrose in water and 
lactated ringers solution could be used in the flush 
solution. These other solutions, in the absence of the 
heparin, may be as effective in maintaining patency of 
arterial catheters as 0.9% sodium chloride, but this 
cannot be assumed from the results of this study.
Nurses at the hospital where data were collected 
reported that it was unusual to have 31 catheters and only 
1 loss of patency. Prior to the study it was common in 
that hospital to lose patency in as many as T0% of
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arterial catheters with the use of heparinized flush 
solution. The nurses speculated that the loss of patency 
prior to the study may have been due in part to lack of 
attentiveness in assessing and maintaining the catheters 
by frequent flushing and waveform analysis. During the 
inservice for data collection the nurses were instructed 
to treat all arterial catheters the same; to do nothing 
different to the catheters in the heparin and non-heparin 
groups (Appendix E, item 2). All arterial catheters may 
have been treated differently during this study than they 
were prior to this study. It is possible that they were 
flushed more frequently, the pressure bags delivering 300 
mm Hg pressure were checked and pressure maintained more 
consistently, and the waveforms were analyzed on a more 
regular basis. If this did occur, there may be a 
reasonable possible alternative hypothesis for the 
findings of this study. It may be that there would be a
decrease in the loss of patency in arterial catheters when
the frequency of patency checks is increased.
Although the use of waveform and flush analysis and 
backflow of blood in the pressure line are valid 
measurements of arterial catheter patency (Kaye, 1983; 
Johnson & Ito, 1969; Hudson-Civetta & Banner, 1983; 
Gardener et al., 1970), they may not have been measured
reliably in this study. A self assessment (Appendix F)
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was given to each nurse participating in data collection 
and was to be returned anonymously to the author. The 
nurses may have collaborated in responding on the self 
assessment, which may have altered the responses to the 
measure used to determine interrater reliability of 
waveform and flush analysis. Because only 50% of the self 
assessments were returned, the calculation of interrater 
reliability may have been spuriously high.
Recommendations for Practice
Several studies reported in the literature suggest 
that venous access devices can be maintained without 
heparin (Ashton et al., 1990; Epperson, 1984; Garrelts et 
al., 1989). This study and Hook et al. (1987) suggest 
that arterial catheters can be maintained with 
non-heparinized normal saline solutions.
Recommendations for Future Research
Similar studies on multi-lumen central venous access 
devices and pulmonary artery catheters would be beneficial 
in evaluating the need for heparin in maintaining the 
patency of these devices. It may be possible that clients 
could be spared the insult of the stressor heparin in all 
types of invasive catheters.
Comparing different intervals of arterial catheter 
patency checks could help answer the question that arose 
from this study; why was there less loss of patency during 
the study than prior to the study? More meticulous care
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of arterial catheters and the flush system may 
significantly decrease the incidence of loss of patency.
Solutions other than normal saline may not be as 
effective in maintaining patency of arterial catheters in 
the absence of heparin. The AACN Thunder Project study 
protocol did not limit the study sites to normal saline.
It was the only base solution used in this study because 
it was the standard solution used by the hospital in flush 
systems. Future research using a variety of solutions is 
needed.
Implications
The findings of this study and Hook et al. (1987), 
provide implications for nursing practice. The studies 
suggest that a change of policies which specify the 
routine use of heparin in flush solutions of arterial 
catheters might be appropriate. This would benefit 
clients by reducing exposure to a created stressor, 
heparin. Comparing changes in platelet counts between 
groups receiving heparinized and non-heparinized flush 
solutions could provide valuable information on the effect 
of low dose heparin in the development of 
thrombocytopenia. More studies are needed before any 
policy changes should be made. These studies should 
include larger samples, examine the frequency of patency 
checks, and use subjects with diverse medical diagnoses.
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Site Coordinator Acceptance
July 23,1991
Juanita Bogart, RN, ESN, CCRN
ICU Charge Nurse
Battle Creek Health System - Leila
300 North Avenue
Battle Creek, MI 49016
Dear Juanita:
Welcome to the educational and data collection phases of Thunder PmjecC* .^ Your educational package 
and 60 data collection packages will be arriving within 5 working days by UPS. You may want to alert your 
institutional mail service to be eaqpecting this delivery. The boxes are prominentfy labeled, Thunder Project''**.
Endœed are the Thunder Project’''* pre-randomized Master Data Lists for your institution. As patients 
enter the study, they are consecutively placed on the data list and receive their assignment to the heparin or non­
heparin treatment groups based on their position on the list As discussed in your materials, you will need to 
keep the lists in a central location for use by Site Research Assodates.
You have been assigned the institutional number of 094. This number needs to appear on all data 
collection forms and on the institutional description form which will come with your educational materials.
If you do not receive your materials promptly or if you have questions when they arrive, call the 
Research Department at the National Office for assistance. The office now has extended hours from 7:30 AM 
to 5:30 PM Monday through Friday, West Coast time. Also, you may call and leave a message with the 
answering service at any time.
Sincerely,
Karen R. Sechrist, PhD, RN, FAAN 
Director of Research 
Thunder Project"* Task Force 
Staff Liaison
AACN
AMERICAN’ A SSO C IA T IO N
O F  CRITICA L CAKE N URSES
PC) II,IS HODIIK
Lauuna NmucI, CA
714(144.9310
FAX 7 1 4 .6 4 0 4 9 0 3
TL.X 29(,937 AACN UK
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.G RAND  
VALLEY 
STATE 
UNIVERSITY
1 CAMPUS DRIVE •  ALLENDALE MICHIGAN 49401-9403 •  616/895^611
Approval by Human Subjects Review
December 12, 1991
Juanita Bogart 
22109 Waubascon Rd.
Battle Creek, MI 49017
Dear Juanita:
The Human Research Review Committee of Grand Valley State University is 
charged to examine proposals with respect to protection of human subjects. The 
Committee has considered your proposal, ''Comparison of the Efficacy of 
Heparinized and Non-heparinized Solutions in Maintaining Phtency of Arterial 
Catheters", and is satisfied that you have complied with the intent of the 
regulations published in the Federal Register 46 (16): 8386-8392, January 26, 
1981.
Please note that approval is contingent upon the following modifications.
1. When using the Informed Consent form with patients use a 
shortened and easier version for them to understand.
2. In the Informed Consent document - change the last sentence 
of the fourth paragraph to read - Risks are present whether 
you choose to participate or not participate in this study.
3. In the Patient Acknowledgement section, the quotation marks 
should be omitted and you should include a contact person
at the Battle Creek Health Center who the subject can contact 
in the event of questions.
Sincerely,
Paul Huizenga, Chair 
Human Research Review Comn '
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Acceptable Square Wave Test 
Figure 2
Accaptabte Sauara Wav» Dampened Scniaw Wava
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"If the patient has received any of the following from sources 
other than the arterial line in the study during the previous 4  
hour of data collection, indicate yes in the thrombolytics/ 
anticoagulants data collection column:
Anticoagulants
Acelykalicylie acid (Aspirin)
Dipyridamole (Perandn)
Sulfinpyrazone (Anturane)
Heparin sodium (Hepaiean, Heparin Lock Flush Solution. Hep 
Lock. Uquaemin Sodium)
Heparin calcium (Calcilean. Caldparine)
Warfarin sodium (Coumadin. Panwarfin, Wbrfilorw Sodum.
Carfin. Sofarin)
Dicumarol (Dicoumarin)
Anisindione (Miradon)
Thmmbolvties
Tissue plasminogen activator (t-PA) or Alteplasa (Activase)
APSAC or Anistreplase (Eminase)
Streptokinase (Kabikinase, Streptase)
\
COMMENTS
UNE
NUMBER
1
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AACN
CRITICAL CARE
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AACN THUNDER PROJECT !
COMMENTS SHEET '
"K  ttw patient has received any of the following from sources 
other than the arterial line in the study during the previous 4  
hour of data collection, indicate yes in the thrombolytics/ 
anticoagulant! d s a  enliaetian column:
Anticoagulants
Acetyfsaiicyiic add  (Aspirin)
Dipyridamole (Petsamm)
Sulfinpyrazone (Anturane)
Kst^rin sodium (Hepaban. Heparin lock Flush Solution. Hep 
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Warfarin sodium (Coumadin. Panwarfin. Warfilone Sodium.
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Streptokinase (Kabikinase. Streptase)
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Appendix E
Appendix E
Guidelines for Data Collection 
AACN THUNDER PROJECT»^
SITE RESEARCH ASSOCIATE INFORMATION SHEET
Accuracy and consistency during data collection is of critical inçortance during the Thunder 
Project" .^ We would like to ask your cooperation in helping to maintain consistency and 
accuracy during data collection in the following areas.
1. Maintain your standard procedures for maintenance of arterial lines. Do not 
change your technique, flushing or positioning procedures during the study. 
It is important that your usual standard of care is maintained.
2. Treat all arterial lines the same. Do nothing different to patients in the 
heparin and non-heparin groups.
3. Do not flush arterial lines with a syringe prior to performing the square wave 
test
4. Collect data in the order indicated on the data collection form, check arterial 
pressure hzg, adjust pressure if indicated, perform square wave test check for 
arterial backflow, determine if patient has received anticoagulants or 
thrombolytics in the last four hours.
5. Do not skip any data collection points. If a data collection point is missed by 
up to 60 minutes, perform the data collection and fill in the data. If the data 
collection is missed by greater than 60 minutes, omit the data collection point 
and make a written comment on the appropriate line in the comments section.
6. If the arterial flush solution is changed (lactated ringers to saline, for example) 
indicate the change on the comments lines.
7. At no time should the patient be changed from the heparin to non-heparin 
group or vice versa. Should the physician order such a ^ ange in the solution, 
the data collection should be terminated and the patient removed from the 
study.
8. Indicate any unusual situations or changes on the comments section. Fill in 
the circles where indicated. Please do not write on the data collection form 
except in the comments section.
9. If any untoward events occur while the patient is in the study, notify the site 
"coordinator for instructions.
10. Enjoy your participation in Thunder Projea^l
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Appendix F
Self Assessment
Darken the ^>propriate drde to indicate Aether the sançle square wave is acceptable or 
dampened.
Example Exanq)le
4.
Acceptable square wave Oyes Q n o  Acceptable square wave Oyes O no
2. 5.
Acceptable square wave O y e s  Q n o  Acceptable square wave O y e s  O n o
3. 6.
Acceptable square wave O  51 O n o  Acceptable square wave O y e s  O n e
Appendix G
Appendix G
Informed Consent
Comparison of the Efficacy of 
Heparinized and Non-heparini zed Solutions 
in Maintaining Patency of Arterial Catheters
You are being asked to participate in a national multisite 
research study developed by the American Association of Critical 
Care Nurses. The study will evaluate the effects of heparinized 
and non-heparinized flush solutions in maintaining an open and 
functioning arterial catheter. The results of the study will help 
determine which solution will best keep arterial catheters open 
and working. During this study you will be placed into one of two 
groups of patients. One group will have heparin in the flush 
solution and the other will not. The decision to participate in 
the study will not change the care you will receive and will not 
involve any additional costs beyond those incurred during normal 
care.
If clots form in the tubing, your doctor may have to remove the 
arterial line. In very rare cases, a clot may cause a decrease or 
loss of blood supply to the area beyond the catheter location. 
Risks are present whether you choose to participate or not 
participate in this study.
There are no immediate personal benefits to participation in the 
study. Withdrawal from the study once data collection has begun 
may or may not change the flush solution you receive.
Patient Acknowledaemmnt
I have been given an opportunity to ask questions regarding this 
research study, and these questions have been answered to my 
satisfaction. I understand that if I have any additional 
questions I can contact Juanita Bogart, RN, at (615) 963-0436 or 
(616) 966-8555.
In giving my consent, I understand that my participation in this 
research project is voluntary, and that I may withdraw at any time 
without affecting my future medical care.
I understand that this study is part of a national study by the 
American Association of Critical Care Nurses and endorsed by the 
Society of Critical Care Medicine. I also understand that the 
investigator, Juanita Bogart, RN will use the information 
collected on all of the study participants at Battle Creek Health 
System to complete a thesis project for a Master of Science in 
Nursing degree from Grand Valley State University. I hereby 
authorize the investigator, Juanita Bogart, to release the 
information obtained in this study to the American Association of 
Critical Care Nurses for statistical analysis and to Grand Valley 
State University. I understand that results will be reported as 
group findings and not by individual names.
1 understand that neither Battle Creek Health System, Grand Valley 
State University, nor Juanita Bogart agree to bear the expense of 
medical care for any new illness or complications which may 
develop during my participation in this study.
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Appendix G
Informed Consent
"I acknowledge that I have read and understand the above 
information, and that I agree to participate in this study, 
have received a copy of this document for my o%m records. *
Participant Date
Witness Date
The patient  __________ is unable to provide informed
consent due to his/her medical condition, consent is being 
obtained from a family member/guardian.
Family Member/Guardian Date
Relationship Witness/Date
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